BiotechTube

Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drugs, Investigational

Conditions

Drugs, Investigational

Trial Timeline

Apr 29, 2010 → Aug 6, 2010

NCT ID
NCT01122602

About Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo

Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo is a phase 3 stage product being developed by Bayer for Drugs, Investigational. The current trial status is completed. This product is registered under clinical trial identifier NCT01122602. Target conditions include Drugs, Investigational.

What happened to similar drugs?

0 of 2 similar drugs in Drugs, Investigational were approved

Approved (0) Terminated (0) Active (2)
🔄HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
🔄Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01122602Phase 3Completed

Competing Products

6 competing products in Drugs, Investigational

See all competitors
ProductCompanyStageHype Score
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
SHR-1603Jiangsu Hengrui MedicinePhase 1
33
Famitinib + Ifosfamide + CamrelizumabJiangsu Hengrui MedicinePhase 1/2
24
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)Gilead SciencesPre-clinical
26
SintilimabInnovent BiologicsPhase 2
35
Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + PlaceboBayerPhase 3
37